California-based Amgen has filed a patent infringement suit to stop Samsung Bioepis from developing bone-treatment drugs that would rival two of its top-performing products.
Who Got the Work: Saul Ewing Team Appears for Samsung Bioepis in Amgen Patent Case
Leave a Reply